These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21751757)

  • 1. Heart failure: ivabradine is no better than optimised beta-blocker therapy.
    Prescrire Int; 2011; 20(118):189-90. PubMed ID: 21751757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N; Bhargava B
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
    Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr; 16(88):53-6. PubMed ID: 17458043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
    Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
    Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
    Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker).
    Dimopoulos K; Salukhe TV; Coats AJ; Mayet J; Piepoli M; Francis DP
    Int J Cardiol; 2004 Feb; 93(2-3):105-11. PubMed ID: 14975535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
    Di Franco A; Sarullo FM; Salerno Y; Figliozzi S; Parrinello R; Di Pasquale P; Lanza GA
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):101-10. PubMed ID: 24327100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.